Eiji Higashihara

Summary

Affiliation: Kyorin University School of Medicine
Location: Mitaka, Tokyo, Japan
Summary:
Title: Professor and Chairman, Department of Urology, Kyorin University School of Medicine
Curriculum Vitae:
March 1972 Graduated from Tokyo University School of Medicine
April 1972 Clinical Fellow, Department of Urology, Tokyo University School of Medicine
July 1976 Research Fellow, Department of Nephrology, Health Science Center at Dallas, University of Texas
April 1982 Associate Professor, Department of Urology, Yamanashi Medical School
Sept. 1982 Visiting Associate Professor, Department of Nephrology, Health Science Center at Dallas, University of Texas
Nov. 1983 Assistant Professor, Department of Urology, Tokyo University School of Medicine
June 1988 Associate Professor, Department of Urology, Tokyo University School of Medicine
April 1994 Professor and Chairman, Department of Urology, Kyorin University School of Medicine
Nov. 2004 Scientific Advisory Board of TEMPO (Tolvaptan Efficacy and safety in Management of Polycystic kidney disease and its Outcome) global study.
April 2006 President of Kyorin University Hospital
Prior experience of committee members in the organization of medical conferences:
Chairman (Past) Japanese Society of Endourology and ESWL
President (Past) 16th Congress of Japanese Society of Endourology and ESWL in 2002
The 1st Annual Meeting of the East Asian Society of Endourology(EASE) in 2004
17th Congress of Japan Society for Endoscopic Surgery in 2004
49th Congress of Japanese Society of Nephrology in 2006
73th Congress of Japanese Society of Urology, Eastern Section in 2008
  Honorary President   29th World Congress of Endourology and SWL in 2011
Board (Past): Société Internationale d’Urologie (SIU), Japanese Society of Nephrology, Japan Society for Endoscopic Surgery, Japanese Society of Endourology and ESWL, Japanese Society for Therapeutics and Engineering
Award:
Nov. 2001 Japan Kidney Foundation, Academic Award
March 2002 Tokyo Medical Association, Award for Group Research
Feb. 2007 The Japanese Foundation for Research and Promotion of Endoscopy, Award
Publications:
1) Eiji Higashihara, Thomas D.DuBose, Juha P.Kokko. Direct examination of chloride transport across papillary collecting duct of the rat. Am J Physiol. 253(3): F219-226, 1978.
2) Eiji Higashihara, John B.Stokes,Juha P.Kokko,William B.Campbell, Thomas D.DuBose. Cortical and papillary micropuncture examination of chloride transport in segments of the rat kidney during inhibition of prostaglandin production. J Clin Invest. 64: 1277-1287, 1979.
3) Eiji Higashihara, Kikuo Nutahara, Kiichiro Tago, Akira Ueno, Tadao Niijima. Renal function studies in cystic renal disease. Jpn J Nephrol. 23:1021-1026, 1981.
4) Eiji Higashihara, Kikuo Nutahara, Kiichiro Tago, Akira Ueno, Tadao Niijima. Renal hypercalciuria associated with medullary sponge kidney. Proceedings of congres de la societe internationale urologie. P.109-112, 1982.
5) Eiji Higashihara, Kikuo Nutahara, Kiichiro Tago, Akira Ueno, Tadao Niijima. Medullary sponge kidney and renal acidificantion defect. Kidney Int. 25: 453-459, 1984.
6) Eiji Higashihara, Norman W.Carter, Leo Pucacco, Juha P.Kokko. Aldosterone effects on papillary collectiong duct pH profile of the rat. Am J Physiol. 246: F725-F731, 1984.
7) Eiji Higashihara, Juha P. Kokko. Effects of aldosterone on potassium recycling in the kidney of adrenalectomized rats. Am J Physiol. 248: F219-F227, 1985.
8) Eiji Higashihara, Venugopal Pillai, Juha P. Kokko. Cortical and papillary micropuncture study of water transport in segments of the rat kidney during inhibition of prostaglandin synthesis. Jpn J Nephrol. 27: 1317-1328, 1985.
9) Eiji Higashihara, Hiromu Tokuda, Hiroichi Kishi, Tadao Niijima, Yoshitaka Okada, Junichi Nishikawa, Masahiro Iio. Technetium-99m dimercaptosuccinic acid uptake in long-term catheterized kidney: comparison with renal function. Urology. 31: 327-331, 1988.
10) Eiji Higashihara, Kikuo Nutahara, Tadao Niijima. Renal hypercalciuria and metabolic acidosis associated with medullary sponge kidney: effect of alkali therapy. Urol Res. 16:95-100, 1988.
11) Shuji Kameyama,Eiji Higashihara,Shigeru Minowada,Hiroichi Kishi, Takashi Umeda, Yoshio Aso. Treatment of renal staghorn calculi by percutaneous nephrolithotripsy with or without extracorporeal shock wave lithotripsy. Jpn J Endourol ESWL. 1:(2) 26-30, 1988.
12) Kikuo Nutahara, Eiji Higashihara, Yasunori Ishii,Tadao Niijima. Renal hypercalciuria and acidification defect in kidney stone patients. J Urol. 141: 813-818, 1989.
13) Eiji Higashihara, Yoshio Aso. Flexible ultrasonotrite and fiberoptic ureterorenoscope: A new approach to ureteral calculi. J Urol. 142: 40-42, 1989.
14) Akira Kimura, Eiji Higashihara, Yoshio Aso. Oblique pyelography for focusing of extracorporeal shock wave lithotripsy. Jpn J Endourol ESWL. 2: 34-36, 1989.
15) Eiji Higashihara, Yasuyuki Asakage, Takashi Tominaga, Toru Hara, Akira Kimura, Hiroichi Kishi, Tadao Niijima, Yoshio Aso. Effect of shock wave application on the kidney: comparisons with open surgery. Jpn J Endourol ESWL. 2: 89-96, 1989.
16) Hidetoshi Kawashima, Manabu Mochizuki, Atsushi Okumura, Yujiro Fujino, Tsuyoshi Tange, Daitaro Horiuchi, Eiji Higashihara, Hidehiko Kaku, Goro Inaba. Cyclosporine G and D in experimental autoimmune uveoretinitis in the rat. Jpn J Ophthalmol. 33: 425-440, 1989.
17) Eiji Higashihara, Shigeo Horie, Takumi Takeuchi, Kikuo Nutahara, Yoshio Aso. Long-term consequences of nephrectomy. J Urol. 143: 239-243, 1990.
18) Eiji Higashihara, Shigeo Horie, Takumi Takeuchi,Shuji Kameyama, Yasuyuki Asakage, Yoshio Hosaka, Yukio Homma, Shigeru Minowada, Yoshio Aso. Laser ureterolithotripsy with combined rigid and flexible ureterorenoscopy. J Urol. 143: 273-274, 1990.
19) Eiji Higashihara, Shigeru Minowada, Shuji Kameyama, Yoshio Aso. Angled optical axis for central viewing of endoscopic accessories. J Endourol. 4: 361-364, 1990.
20) Eiji Higashihara, Kikuo Nutahara, Takumi Takeuchi, Nobuyuki Shoji, Makoto Araie, Yoshio Aso. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. J Urol. 145: 942-948, 1991.
21) Nobuo Moriyama, Yasushi Nagase, Naoto Doi, Eiji Higashihara, Isao Murahashi, Yoshio Aso. Localization of estrogen, epidermal growth factor, and transferring receptors in human prostatic carcinoma. Acta Histochem Cytochem. 24: 61-67, 1991.
22) Takashi Igarashi, Kazuhiko Shibuya, Shigehiko Kamoshita, Eiji Higashihara, Hidehiko Kawato, Kyoko Hagishima, Takeshi Kosugi. Renal cyst formation as a complication of primary distal renal tubular acidosis. Nephron. 59: 75-79, 1991.
23) Shigeru Minowada, Eiji Higashihara, Shuji Kameyama, Takumik Takeuchi, Masaya Oshi, Kikuo Nutahara, Yukio Homma, Yoshio Aso. Transurethral lithotripsy for upper urinary tract using fiberoptic nephroureteroscope. Jpn J Endourol ESWL. 4: 172-175, 1991.
24) Eiji Higashihara, Yoshio Aso, Jun Shimazaki, Haruo Ito, Kenkichi Koiso, Osamu Sakai. Clinical aspects of polycystic kidney disease J Urol. 147: 329-332, 1992.
25) Shigeru Minowada, Eiji Higashihara, Shuji Kameyama, Masaya Oshi, Yukio Homma, Yoshio Aso. Advantage of a smaller caliber fiberscope and learning curve on transurethral lithotripsy. J Urol. 147: 1243-1244, 1992.
26) Eiji Higashihara, Kikuo Nutahara, Shigeru Minowada, Yukio Homma, Yoshio Aso. Percutaneous reduction of cyst volume of polycystic kidney disease:Effects on renal function. J Urol. 147: 1482-1484, 1992
27) Nobuo Moriyama, Eiji Higashihara, Tetsuo Ueki, Yoshio Hosaka, Shigeharu Kurimoto, Yasunori Ishii, Atsushi Tajima, Yoshio Aso. Acta Histochem Cytochem. 25: 421-429, 1992.
28) Kikuo Nutahara, Eiji Higashihara, Takumi Takeuchi, Yoshio Aso. Clinical application for upper urinary tract stones using Dornier lithotripter compact. Jpn J Endourol ESWL. 5: 186-190, 1992.
29) Takumi Takeuchi, Eiji Higashihara, Kaoru Nomura, Nobuo Moriyama, Yoshio Aso, Hiroshi Demura. The renotropic effect of ovine luteinizing hormone on subtotally nephrectomized rats. Endocrinol Japon. 39: 109-114, 1992.
30) Shigeharu Kurimoto, Eiji Higashihara, Nobuo Moriyama, Atsushi Tajima, Yoshio Aso, Kuniaki Takata and Hiroshi Hirano. Ultrastructural observations on a case of papillary carcinoma of the prostate. J Clin Electron Micrsc. 25: 576-577, 1992.
31) Eiji Higashihara, Yoshinori Tanaka, Shigeo Horie, Seiji Aruga, Kikuo Nutahara, Shigeru Minowada, Yoshio Aso. Laparoscopic adrenalectomy: The initial three cases. J Urol. 149: 973-976, 1993.
32) Shigo Horie, Eiji Higashihara, Kikuo Nutahara, Yasuyo Mikami, Akiyuki Okubo, Munehide Kano, Kazuki Kawabe. Mediation of renal cyst formation by hepatocyte growth factor. Lancet. 344: 789-791, 1994.
33) Yukihiko Sasaki,Eiji Higashihara,Takumi Takeuchi,Kikuo Nutahara,Yukio Homma,Yoshio Aso. A case of familialcentral diabetes insipidus:The response of urinary prostaglandins to 1-Deamino-8-D-Srginine vasopressin.J Urol. 152:161-163,1994.
34) Eiji Higashihara, Shigo Horie. Genetic study of ADPKD in Japan. Kidney Int. 47: 729,1995.
35) Huiru Wang, Shoji Kuwata, Takeo Juji, Masami Yanagisawa, Katsushi Tokunaga, Shigeo Horie, Eiji Higashihara, Kiyoshi Kurokawa, Hiroshi Yoshikura, Yoichi Shibata. Ethnic Differences in Allele Frequencies of Two Microsatellite Markers Closely Linked to the Locus for Polycystic Kidney Disease 1 (PKD1). Hum Heredity. 45: 84-89、1995.
36) Eiji Higashihara. Technical and Anatomical Aspects of the Double Blood Supply Method: One Stage Urethroplasty for Hypospadia Repair. Akt Urol.27: 13-14, 1996 (Supplement).
37) Eiji Higashihara, Kikuo Nutahara. Laparoscopic Adrenalectomy. Akt Urol 27:15-16,1996(Supplement).
38) Eiji Higashihara, Kikuo Nutahara, Miho Kojima, Takatsugu Okegawa, Ichiro Miura, Akiomi Miyata, Moriaki Kato, Hajime Sugisaki Takeshi Tomaru. Significance of free prostate specific antigen and gamma-seminopotein in the screening of prostate cancer. The Prostate. 7: 40-47, 1996. (Supplement)
39) Eiji Higashihara, Kikuo Nutahara, Miho Kojima Takatsugu Okegawa, Ichiro Miura, Akiomi Miyata, Moriaki Kato, Hajime Sugisaki Takeshi Tomaru. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol. 156: 1964-1968, 1996.
40) Shigeo Horie, Munehide Kano, Eiji Higashihara, Nobuo Moriyama, E Tanaka, A Hirose, Tadao Kakizoe, Kazuki Kawabe. Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol. 27(6):384-388, 1997.
41) Eiji Higashihara, Shiro Baba, Ken Nakagawa, Masaru Murai, Hideto Go, Masayuki Takeda, Kota Takahashi, Kazuo Suzuki, Kimio Fujita, Yoshinari Ono, Shinichi Ohshima, Tadashi Matsuda, Toshiro Terachi Osamu Yoshida. Learning curve and conversion to open surgery in cases of laparoscopic adrenalectomy and nephrectomy. J Urol. 159: 650-653, 1998.
42) Takatsugu Okegawa, Junichi Yoshioka, Ryoji Morita, Kikuo Nutahara, Yutaka Tsukada, Eiji Higashihara. Molecular Staging of Prostate Cancer: Comparison of Nested Reverse Transcription Polymerase Chain Reaction Assay Using Prostate Specfic Antigen Versus Prostate Specific Memberane Antigen as Primer. Int. J Urol. 5: 349-356, 1998.
43) Eiji Higashihara, Kikuo Nutahara, Masayo Kojima, Akiko Tamakoshi, Ohno Yoshiyuki, Hideto Sakai, Kiyoshi Kurokawa. Prevalence and Renal Prognosis of Diagnosed Autosomal Dominant Polycystic Kidney Disease in Japan. Nephron. 80: 421-427, 1998.
44) Kunimasa Yan, Akihiko Kudo, Hiroshi Hirano, Takashi Watanabe, Tetsuya Tasaka, Saeko Kataoka, Noriko Nakajima, Yukino Nishibori, Toru Shibata, Takao Kohsaka, Eiji Higashihara, Hirotoshi Tanaka, Hidehiro Watanabe, Toshihiko Nagasawa, and Shouichi Awa. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int. 56: 65-73, 1999.
45) Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. BJU Int. 84: 112-117, 1999.
46) Kikuo Nutahara, Moriaki Kato, Akiomi Miyata, Akihiro Murata, Takatsugu Okegawa, Ichiro Miura, Miho Kojima, Eiji Higashihara. Comparative study of pulsed dye laser and pneumatic lithotripters for transurethral ureterolithotripsy. Int J Urol. 7: 172- 175, 2000.
47) Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol. 163:1183- 1188, 2000.
48) Takatsugu Okegawa, Kazuyoshi Watanabe, Haruhisa Noda, Moriaki Kato, Akiomi Miyata, Akihiro Murata, Masahito Yoshii, Kikuo Nutahara, Eiji Higashihara. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0ng/mL. BJU Int. 85:708- 714, 2000.
49) Takatsugu Okegawa, Haruhisa Noda, Kikuo Nutahara, Eiji Higashihara.Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0ng/mL. Urology. 55:700- 704, 2000.
50) Takatsugu Okegawa, Haruhisa Noda, Kikuo Nutahara, Eiji Higashihara. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Euro Urol. 38: 380- 387, 2000.
51) Takatsugu Okegawa, Haruhisa Noda, Moriaki Kato, Akiomi Miyata, Kikuo Nutahara, Eiji Higashihara.Value of reverse transcription polymerase chain reaction assay in pathological stage T3NO prostate cancer. The Prostate. 44: 210- 218, 2000.
52) Takatsugu Okegawa, Yingming Li, Rey-Chen Pong, Jeffrey M.Bergelson, Jian Zhou, Jer-Tsong Hsieh. The Dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer res. 60: 5031- 5036, 2000.
53) T Terachi, O Yoshida, T Matsuda, S Orikasa, Y Chiba, K Takahashi, M Takeda, Eiji Higashihara, M Murai, S Baba, K Fujita, K Suzuki, S Ohshima, Y Ono, J Kumazawa, S Naito:Complications of laparoscopic and retroperitoneoscopic adrenalectomies in 370 cases in Japan: a multi-institutional study. Biomed Pharmacother 54 Suppl 1:211s-214s, 2000.
54) Michiko Mizoguchi, Takashi Tamaura, Akihiko Yamaki, Eiji Higashihara, Yoshiko Shimizu. Mutations of the PKD1 gene among Japanese autosomal dominant polycystic kidney disease patients, including one heterozygous mutation identified in members of the same family. J Hum Genet. 46: 511- 517, 2001
55) Takatugu Okegawa,Moriaki Kato,Akiomi Miyata,Kikuo Nutahara, Eiji Higashihara. The prognostic value of 3 molecular forms of prostate specific antigen ratios in patients with adenocarcinoma of the prostate.Urology. 57(5):936- 942,2001.
56) Takatugu Okegawa,Haruhisa Noda,Masaya Ohta,Moriaki Kato,Kikuo Nutahara, Eiji Higashihara. The use of various combinations of free, complexed, and total prostate specific antigen as predictors of the pathological stage of prostate cancer.Int J Urol. 8(8):438-443,2001.
57) Saeko Kataoka, Akihiko Kudo, Hiroshi Hirano, Hayato Kawakami, Toshio Kawano, Eiji Higashihara, Hirotoshi Tanaka, Francoise Delarue, Jean-Daniel Sraer, Tomoatsu Mune, Zygmunt S. Krozowski, and Kunimasa Yan. 11β-Hydroxysteroid Dehydrogenase Type 2 Is Expressed in the Human Kidney Glomerulus. J Clin Endocrinol Metab. 87: 877- 882, 2002
58) Satoru Muto, Atsu Aiba, Yuichirou Saito, Kazuki Nakao, Kenji Nakamura, Kyoichi Tomita, Tadaichi Kitamura, Masahiko Kurabayashi, Ryozo Nagai, Eiji Higashihara, Peter C. Harris, Motoya Katsuki, Shigeo Horie. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 11: 1731- 1742, 2002
59) Kikuo Nutahara, Eiji Higashihara, Akito Yamaguchi, and Mikio Kanemura. Review of the clinical guidelines for staghorn caluli. Recent Advances Endourol. 4:85- 91, 2002.
60) Takatsugu Okegawa, Manami Kinjo, Shigeo Horie, Kikuo Nutahara, Eiji Higashihara. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology. 62(1): 182- 186, 2003.
61) Takatsugu Okegawa, Manami Kinjo, Masaya Ohta, Ichiro Miura, Shigeo Horie, Kikuo Nutahara, Eiji Higashihara. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol. 10: 201- 206, 2003
62) Hisamitsu Ide, L Xin, Eiji Higashihara, ON. Colony stimulating factor-1 receptor signaling enhances tumorigenesis and invasion of prostate cancer cells. Proceedings of the eighth workshop on prostate cancer, Tokyo:22-55, 2003.
63) Takatsugu Okegawa, Manami Kinjo, Kikuo Nutahara, Eiji Higashihara. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol. 171: 1461-1466, 2004
64) Yukino Nishibori, Li Liu, Makoto Hosoyamada, Hitoshi Endou, Akihiko Kudo, Hitoshi Takenaka, Eiji Higashihara, Fumio Bessho, Shori Takahashi, David Kershaw, Vesa Ruotsalainen, Karl Tryggvason, Jamshid Khoshnoodi, and Kunimasa Yan. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane. Kidney Int. 66: 1755- 1765, 2004
65) Moriaki Kato, Hiroko Igarashi, Akiko Takeda, Shigeo Horie, Eiji Higashihara, Tesuro Matano. Stimulation of virus-specific T cell responses by dendritic cell vaccination in the chronic phase of simian AIDS models. Jpn J Infect Dis.57: 220- 223, 2004
66) Manami Kinjo, Takatsugu Okegawa, Shigeo Horie, Kikuo Nutahara, Eiji Higashihara. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol. 11(1): 38-43, 2004.
67) Kikuo Nutahara, Eiji Higashihara, Shigeo Horie, Kouichi Kamura, Ken Tuchiya, Toshio Mochizuki, Tatsuo Hosoya, Tomohiro Nakayama, Norio Yamamoto, Yoshio Higaki, Toshiko Shimizu. Calcium channel blocker versus Angiotensin Ⅱ receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 99: c18- c23, 2005
68) Takatsugu Okegawa, Kikuo Nutahara, Rey-Chen Pong, Eiji Higashihara, Jer-Tsong Hsieh. Enhanced transgene expression urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol. 174 : 747- 752, 2005
69) Moriaki Kato, Hiroko igarashi, Akiko Takeda, Yuri Sasaki, Hiromi Nakamura, Munehide Kano, Tetsutaro Sata, Akihiro Iida, Mamoru Hasegawa, Shigeo Horie, Eiji Higashihara, Yoshiyuki Nagai, Tetsuro Matano. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine. 23: 3166- 3173, 2005
70) HP Neumann, M Cybulla, S H hibata, M Oya, M Naruse, Eiji Higashihara, T Terachi, H Ling, H Takami, T Shuin, M Murai. New genetic causes of pheochromocytoma: current concepts and the clinical relevance. Keio J Med. 54(1):15-21, 2005.
71) Takatsugu Okegawa, Akihiro Odagane, Hisamitsu Ide, Shigeo Horie, Kikuo Nutahara, Eiji Higashihara. Oncological outcome of retoroperitoneoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. Int J Urol. 13: 493- 497, 2006.
72) Takatsugu Okegawa, Manami Kinjo, Kikuo Nutahara, Eiji Higashihara,. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 13: 1197-1201, 2006.
73) Takatsugu Okegawa, Akihiro Odagane, Kikuo Nutahara, Eiji Higashihara. Laparoscopic management of urachal remnants in adulthood. Int J Urol. 13: 1466-1469, 2006
74) Kei Hamazaki, Eiji Higashihara, Toshiro Terachi, Hideho Takada, Tadasshi Matsuda, Mutsushi Kawakita, Hideki Fuse, Tomohito Hamazaki, Shuji Kameyama, Motoyuki Masai, Yutaka Chiba, Masatoshi Tokunaga, Yuzo Furuya, Takatsugu Okegawa, Takashi Murota, Gen Kawa, Miho Itomura. The effect of eicosapentaenoic acid on prostate-specific antigen. In vivo. 20: 397- 402, 2006
75) Takatugu Okegawa, Jennifer R Sayne, Kikuo Nutahara, Rey-Chen Pong, Hossain Saboorian, Wareef Kabbani, Eiji Higashihara, Jer-Tsong Hsieh. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol. 177: 1148-1156, 2007.
76) Hidehiko Hara, Akihiko Kobayashi, Kimiko Yoshida, Masaki Ohashi, Shumpei Ohnami, Eiji Uchida, Eiji Higashihara, Teruhiko Yoshida, Kazunori Aoki. Local interferon-α gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci. 98(3): 455-463, 2007.
77) Mitsuhiro Tambo, Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Prostatic cyst arising around the bladder neck-cause of bladder outlet obstruction : two case reports. Acta Urol Jpn. 53: 401-404, 2007
78) T Shirakawa, S Terao, N Hinata, K Tanaka, A Takenaka, I Hara, K Sugimura, M Matsuo, K Hamada, K Fuji, T Okegawa, Eiji Higashihara, TA Gardner, C Kao, LW Chung, S Kamidono, M Fujisawa, A Gotoh. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther. 18(12):1225-32, 2007.
79) Eiji Higashihara, Kikuo Nutahara, Shigeo Horie, Satoru Muto, Tatsuo Hosoya, Kazushige Hanaoka, Ken Tuchiya, Kouichi Kamura, Kenmei Takaichi, Yoshifumi Ubara, Miho Itomura and Tomohito Hamazaki.The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD. Nephrol Dial Transplant. 23(9): 2847-2852, 2008.
80) Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Immunomagnetic quantification of circulating Tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol. 180: 1342-1347, 2008
81) Takatsugu Okegawa, Haruhisa Noda, Shigeo Horie, Kikuo Nutahara, Eiji Higashihara. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: A single-center experience of 100 cases. Int J Urol.15(11): 957- 960, 2008
82) Hisamitsu Ide, Kiyohiko Hatake, Yuichi Terado, Hiroyuki Tsukino, Takatsugu Okegawa, Kikuo Nutahara, Eiji Higashihara, Shigeo Horie. Seurm level of macrophage colony- stimulating factor is increased in prostate cancer patients with bone metastasis. Hum Cell. 21: 1- 6, 2008.
83) Eiji Higashihara,Tsutomu Nishiyama, Shigeo Horie, Ken Marumo, Tetsuya Mitarai, Tetsuo Koyama, Takeshi Matsuyama,Kiichi Ito, Tomoji Yuno. Hematuria: Definition and screening test methods. Int J Urol. 15: 281- 284, 2008.
84) Eiji Higashihara, Ryohei Hattori, Ken Nakagawa, Masatsugu Iwamura, Tomomi Ushiyama, Gaku Kawabata, Tomonori Habuchi. How to use laparoscopic surgical instruments safely. Int J Urol. 16: 225, 2009.
85) Takatsugu Okegawa, Kikuo Nutahara , Eiji Higashihara. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 181(3): 1091-1097, 2009.
86) Hidehiko Hara, A Kobayashi, K Narumi, A Kondoh, K Yoshida, T Nishimoto, M Ohashi, Eiji Higashihara, S Ohnami, T Yoshida, K Aoki. Intratumoral interferon- alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother.58: 1007- 1021, 2009.
87) Mitsuhiro Tanbo, Eiji Higashihara, Y Terada, Kikuo Nutahara, Takatsugu Okegawa. Comparison of serum HER2/ neu with immunohistochemical HER2/ neu expression for the prediction of biochemical progression in metastatic prostatic cancer. Int J Urol. 16: 369- 374, 2009.
88) Shuji Terao, Toshiro Shirakawa, Bishnu Acharya, Masahiro Miyata, Nobuyuki Hinata, Kazushi Tanaka, Atsushi Takenaka, Isao Hara, Michio Naoe, Kohzo Fuji, Takatsugu Okegawa, Eiji Higashihara, Sadao Kamidono, Masato Fujisawa, Akinobu Gotoh. A pilot study of quality of life of patients with hormone refractory prostate cancer after gene therapy. Anticancer res. 29: 1533- 1538, 2009.
89) Yuji Sekine, Yukino Nishibori, Yoshihiro Akimoto, Kudo Akihiko, Noriko Ito, Daisuke Fukuhara, Ryota Kurayama, Eiji Higashihara, Ellappan Babu, YOshikatsu Kanai, Katsuhiko Asanuma, Michio Nagata, Arindam Majumdar, Karl Tryggvason, Kunimasa Yan. Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol. 20: 1586- 1596, 2009.
90) Mariko Shimizu, Jamshid Khoshnoodi, Yoshihiro Akimoto, Hayato Kawakami, Hiroshi Hirano, Eiji Higashihara, Makoto Hosoyamada, Yuji Sekine, Ryota Kurayama, Hideaki Kurayama, Kensuke Joh, Jun Hirabayashi, Kenichi Kasai, Karl Tryggvason, Noriko Ito, Kunimasa Yan. Expression of galectin- 1, a new componet of slit diaphragm, is altered in minimal chang nephritic syndrome. Lab Invest. 89: 178- 195, 2009.
91) Takatugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Comparison of laparoscopic and open adrenalectomy for pheochromocytoma in a single center. Asian J Endsc Surg.3(3): 145-149, 2010.
92) Takatugu Okegawa, Kikuo Nutahara, Eiji Higashihara. Association of circulating tumor cells with tumor- related methylated DNA in patients with hormone- refractory prostate cancer. Int J Urol. 17: 466- 475, 2010.
93) Takatugu Okegawa, Kenjiro Hayashi, Hidehiko Hara, Kikuo Nutahara, Eiji Higashihara. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol. 17: 254- 258, 2010.
94) Takatsugu Okegawa, Kikuo Nutahara , Eiji Higashihara. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol. 17(11):950- 955, 2010.
95) Eiji Higashihara, Miho Itomura, Toshiro Terachi, Tadashi Matuda, Mutushi Kawakita, Shuji Kameyama, Hideki Fuse, Yutaka Chiba, Tomohito Hamazaki, Takatsugu Okegawa, Masatoshi Tokunaga, Takashi Murota, Gen Kawa, Yuzo Furuya, Takaya Akashi, Kei Hamazaki and Hideho Takada. Effects of eicosapentaenoic acid on biochemical failure after radical prostatectomy for prostate cancer. In vivo. 24: 561- 566, 2010.
96) Ryota Kurayama, Noriko Ito, Yukino Nishibori, Daisuke Fukuhara, Yoshihiro Akimoto, Eiji Higashihara, Yasuhito Ishigaki, Yoshimichi Sai, Ken-ichi Miyamoto, Hitoshi Endou, Yoshikatstu Kanai, and Kunimasa Yan. Role of Amino Acid Transporter LAT2 in the Activation of mTORC1 Pathway and the Pathogenesis of Crescentic Glomerulonephritis. Laboratory Investigation. 91(7): 992- 1006, 2011.
97) Vicente E. Torres, Esther Meijer, Kyongtae T. Bae, Arlene B. Chapman, Olivier Devuyst, Ron T. Gansevoort, Jared J. Grantham, Eiji Higashihara, Ronald D. Perrone, Holly B. Krasa, John J. Ouyang,and Frank S. Czerwiec. Rationale and design of the TEMPO (Tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3- 4 study. Am J Kidney Dis.57(5): 692- 699, 2011.
98) Eiji Higashihara, Vicente E. Torres, Arlene B. Chapman, Jared J. Grantham, Kyongtae Bae, Terry J. Watnick,Shigeo Horie, Kikuo Nutahara, John Ouyang, Holly B. Krasa, Frank S. Czerwiec, for the TEMPO42 and 156-05-002 Study Investigators. Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years’ Experience. Clin J Am Soc Nephrol. 6: 2499– 2507, 2011.
99) Eiji Higashihara, Shigeo Horie, Satoru Muto, Toshio Mochizuki ,Kikuo Nutahara. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 16(4): 622- 628, 2012.
100) Takatsugu Okegawa, Naoshi Itaya, Hidehiko Hara, Kikuo Nutahara and Eiji Higashihara. Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. Int J Urol. 19: 778- 782, 2012.

Publications

  1. Horie S, Kano M, Higashihara E, Moriyama N, Tanaka E, Hirose A, et al. Expression of Fas in renal cell carcinoma. Jpn J Clin Oncol. 1997;27:384-8 pubmed
    ..These data suggest that Fas targeting may be a therapeutic option for treatment of advanced renal cell carcinoma which is refractory to either chemotherapy or irradiation. ..
  2. Okegawa T, Nutahara K, Higashihara E. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol. 2010;17:466-75 pubmed publisher
    ..Hormone refractory prostate cancer patients with circulating tumor cells and/or tumor-related methylated DNA show a significantly poorer outcome than those without these blood markers. ..
  3. Okegawa T, Nutahara K, Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol. 2009;181:1091-7 pubmed publisher
    ..Circulating tumor cells may be an independent predictor of overall survival in patients with hormone refractory prostate cancer but they may also complement prostate specific antigen. ..
  4. Higashihara E. [Polycystic kidney disease]. Nihon Jinzo Gakkai Shi. 2007;Suppl 50th Ann:83-90 pubmed
  5. Okegawa T, Sayne J, Nutahara K, Pong R, Saboorian H, Kabbani W, et al. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol. 2007;177:1148-56 pubmed
    ..Pretreatment with FK-228 may increase tumor cell sensitivity to adenoviral gene therapy vectors. ..
  6. Kato M, Igarashi H, Takeda A, Sasaki Y, Nakamura H, Kano M, et al. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine. 2005;23:3166-73 pubmed
  7. Okegawa T, Kinjo M, Horie S, Nutahara K, Higashihara E. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology. 2003;62:182-6 pubmed
    ..Our results indicate that MUC7 is a potential marker for bladder cancer. This noninvasive detection method assesses urothelial cells from voided urine specimens using RT-PCR. ..
  8. Higashihara E, Nutahara K, Takeuchi T, Shoji N, Araie M, Aso Y. Calcium metabolism in acidotic patients induced by carbonic anhydrase inhibitors: responses to citrate. J Urol. 1991;145:942-8 pubmed
    ..This event did not occur in patients with normocalciuria or absorptive hypercalciuria. These results suggest that a small amount of citrate could reverse renal hypercalciuria without correcting the metabolic acidosis. ..
  9. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol. 2004;171:1461-6 pubmed
    ..These results seem to indicate that UP II and CK-20 mRNA in the blood may be useful tumor markers for predicting patient survival and the extent of urothelial cancer. ..

Detail Information

Publications36

  1. Higashihara E, Itomura M, Terachi T, Matsuda T, Kawakita M, Kameyama S, et al. Effects of eicosapentaenoic acid on biochemical failure after radical prostatectomy for prostate cancer. In Vivo. 2010;24:561-5 pubmed
    ..16). A longer and/or larger intervention or docosahexaenoic acid supplementation might be necessary to identify significant preventive effects of mega-3 polyunsaturated fatty acids on PSA recurrence. ..
  2. Gotoh A, Shirakawa T, Wada Y, Hinata N, Terao S, Hara I, et al. [Gene therapy]. Hinyokika Kiyo. 2005;51:75-9 pubmed
    ..We look forward to evolution in this field to provide an established treatment for recurrent prostate cancer and are committed to actively continuing with the development of gene therapy through translational research. ..
  3. Okegawa T, Hayashi K, Hara H, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol. 2010;17:254-8 pubmed publisher
    ..004). Based on these findings, CTC could represent a potential marker to monitor the response to chemotherapy in patients with metastatic UC. ..
  4. Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet. 2002;11:1731-42 pubmed
    ..Pathways activated by thiazolidinediones may provide new therapeutic targets in ADPKD. ..
  5. Hamazaki K, Higashihara E, Terachi T, Takada H, Matsuda T, Kawakita M, et al. The effect of eicosapentaenoic acid on prostate-specific antigen. In Vivo. 2006;20:397-401 pubmed
    ..5+/-14.0%). There were no significant differences between the two groups in the serum PSA levels, allowing the conclusion that the PSA is an appropriate surrogate marker of recurrence in prostate cancer. ..
  6. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol. 2006;13:1197-201 pubmed
    ..The pretreatment serum HER2 level may be a useful independent prognostic factor that is associated with a high risk of biochemical recurrence in metastatic prostate cancer patients about to undergo endocrine therapy. ..
  7. Okegawa T, Odagane A, Nutahara K, Higashihara E. Laparoscopic management of urachal remnants in adulthood. Int J Urol. 2006;13:1466-9 pubmed
    ..Mean follow up was 5 (range 4-12) months. There were no postoperative complications. The results suggest that LUR can be safely and satisfactorily performed in adulthood. ..
  8. Mizoguchi M, Tamura T, Yamaki A, Higashihara E, Shimizu Y. Mutations of the PKD1 gene among Japanese autosomal dominant polycystic kidney disease patients, including one heterozygous mutation identified in members of the same family. J Hum Genet. 2001;46:511-7 pubmed
    ..Fifteen single nucleotide polymorphisms were identified in this study. Two of them (C50439A and C51659T) can be used as intragenic polymorphic markers. ..
  9. Terao S, Shirakawa T, Acharya B, Miyata M, Hinata N, Tanaka K, et al. A pilot study of quality of life of patients with hormone-refractory prostate cancer after gene therapy. Anticancer Res. 2009;29:1533-7 pubmed
    ..In this clinical trial, Ad-OC-TK plus VAL treatment significantly improved the short-term QOL and bodily pain of patients with localized recurrence or bone metastases of HRPC. ..
  10. Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther. 2007;18:1225-32 pubmed
    ..All three patients had a PSA response to DE therapy with 21, 7, and 4 months of TTP. These results suggest that additional trials are warranted. ..
  11. Kinjo M, Okegawa T, Horie S, Nutahara K, Higashihara E. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol. 2004;11:38-43 pubmed
    ..007) and grades 2 and 3 (P = 0.025). These results suggest that MUC7 is a highly specific marker for bladder cancer and may be a useful method for the molecular staging and management of bladder cancer. ..
  12. Okegawa T, Nutahara K, Higashihara E. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience. Int J Urol. 2010;17:950-5 pubmed publisher
    ..Patients (52/112, 46.4%) with 30% decrease in PSA levels were associated with significantly better cause-specific survival as measured from the start of first-line treatment and first-line relapse. ..
  13. Hara H, Kobayashi A, Narumi K, Kondoh A, Yoshida K, Nishimoto T, et al. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother. 2009;58:1007-21 pubmed publisher
    ..Graft-versus-host disease was not exacerbated serologically or clinically in the mice treated with IFN-alpha. This combination strategy deserves evaluation in future clinical trials for human solid cancers. ..
  14. Neumann H, Cybulla M, Shibata H, Oya M, Naruse M, Higashihara E, et al. New genetic causes of pheochromocytoma: current concepts and the clinical relevance. Keio J Med. 2005;54:15-21 pubmed
    ..Experiences in this field of medicine have shown that optimal management of patients with pheochromocytoma-associated syndromes is a high challenge. National registries may be instrumental in order to provide with adequate facilities. ..
  15. Okegawa T, Nutahara K, Higashihara E. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. J Urol. 2008;180:1342-7 pubmed publisher
    ..In this study the presence of 5 or more circulating tumor cells in 7.5 ml blood was associated with androgen deprivation responsiveness in patients with metastatic prostate cancer before endocrine therapy. ..
  16. Sekine Y, Nishibori Y, Akimoto Y, Kudo A, Ito N, Fukuhara D, et al. Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol. 2009;20:1586-96 pubmed publisher
    ..Our data suggest that LAT3 may play a crucial role in the development and maintenance of podocyte structure and function by regulating protein synthesis and the actin cytoskeleton. ..
  17. Kato M, Igarashi H, Takeda A, Horie S, Higashihara E, Matano T. Stimulation of virus-specific T cell responses by dendritic cell vaccination in the chronic phase of simian AIDS models. Jpn J Infect Dis. 2004;57:220-3 pubmed
  18. Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL. Int J Urol. 2003;10:201-6 pubmed
    ..001). fPSA/tPSA ratio, fPSA/cPSA ratio, tPSATZ and cPSATZ enhance the specificity of PSA testing compared to tPSA or cPSA when determining which patients should undergo repeat biopsy. ..
  19. Higashihara E, Nutahara K, Horie S, Muto S, Hosoya T, Hanaoka K, et al. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD. Nephrol Dial Transplant. 2008;23:2847-52 pubmed publisher
    ..Administration of EPA with DHA supplementation and/or longer intervention might be necessary to demonstrate preventive effects of omega3-polyunsaturated fatty acids on progression of ADPKD. ..
  20. Higashihara E, Nishiyama T, Horie S, Marumo K, Mitarai T, Koyama T, et al. Hematuria: definition and screening test methods. Int J Urol. 2008;15:281-4 pubmed publisher
  21. Okegawa T, Noda H, Horie S, Nutahara K, Higashihara E. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a single-center experience of 100 cases. Int J Urol. 2008;15:957-60 pubmed publisher
    ..Tumor control and surgical morbidity in laparoscopic radical nephrectomy seem not to be significantly influenced by the approach. ..
  22. Nutahara K, Kato M, Miyata A, Murata A, Okegawa T, Miura I, et al. Comparative study of pulsed dye laser and pneumatic lithotripters for transurethral ureterolithotripsy. Int J Urol. 2000;7:172-5 pubmed
    ..01). Postoperative hospital stay was significantly shorter for Lithoclast (8.7+/-5.1 vs 12.1+/-4.2 days; P<0.01). Swiss Lithoclast is an effective and less invasive modality for endoscopic treatment of lower ureteral stones. ..
  23. Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int. 1999;56:65-73 pubmed
    ..Our findings suggest that all subsets of human glomerular cells definitely express the GR protein, which potentially undergoes translocation by glucocorticoids. ..
  24. Higashihara E, Hattori R, Nakagawa K, Iwamura M, Ushiyama T, Kawabata G, et al. How to use laparoscopic surgical instruments safely. Int J Urol. 2009;16:225 pubmed publisher
    ..In addition, animal models are used to illustrate the potential complications that can be associated with some methods of use. ..
  25. Tambo M, Okegawa T, Nutahara K, Higashihara E. Prostatic cyst arising around the bladder neck-cause of bladder outlet obstruction: two case reports. Hinyokika Kiyo. 2007;53:401-4 pubmed
    ..The lesions were found by abdominal ultrasound examination for post-voiding residual at the first visit. Transurethral unroofing of the cysts was performed with successful resolution of voiding symptoms. ..
  26. Nishibori Y, Liu L, Hosoyamada M, Endou H, Kudo A, Takenaka H, et al. Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane. Kidney Int. 2004;66:1755-65 pubmed
  27. Higashihara E, Horie S, Kinoshita M, Harris P, Okegawa T, Tanbo M, et al. A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. Clin Exp Nephrol. 2018;22:395-404 pubmed publisher
    ..Aforementioned findings indicate that CTT domain's crucial role in renal prognosis needs further investigation by larger studies (ClinicalTrials.gov; NCT02322385). ..